Global anti-inflammatory peptides market is expected to grow over the forecast period owing to the increasing incidences of diseases such as autoimmune diseases, inflammatory bowel disease, multiple sclerosis, and psoriasis. The report published by the World Psoriasis Day in 2013, says that due to consortium, globally 3% to 4% of people are affected by this disease i.e. nearly 130 million people. The other high impact rendering driver for the growth of this market is the rising geriatric population base globally. Aging causes a shift within the natural immunity towards the pro-inflammatory status of the human body, thereby leading to an augmentation in the demand for anti-inflammatory peptides. Other drivers of this market are unhealthy lifestyle and increasing patient awareness levels towards the timely treatment of various disorders.
The anti-inflammatory peptides market is segmented on the basis of applications into cardiovascular diseases, gastrointestinal diseases, dermatological diseases, neurological diseases, otorhino diseases & ophthalmological, respiratory diseases & pulmonary, renal diseases, rheumatological & autoimmune diseases, and transplantation. Among these, the cardiovascular diseases segment held the largest market share in 2014, owing to the rising prevalence of cardiovascular disorders among the global population. Furthermore, factors such as growing incidences of obesity owing to an unhealthy lifestyle and rapidly aging population contributed towards the dominance of this segment.
Geographically, the anti-inflammatory peptides market is studied with respect to five regions, which are, North America, Europe, Asia Pacific, Latin America, and MEA. Among these, North America has dominated the entire market in 2014, as it has the presence of technologically updated systems, strong research & development, and high patient awareness levels in this region. The high incidence rate of both multiple sclerosis and psoriasis is another major factor for North America’s leading position. As per the statistics of the survey conducted by the National Psoriasis Foundation, in 2013 in the U.S. alone there 7.6 million people approximately suffering from psoriasis and nearly 400,000 people have been diagnosed with multiple sclerosis that year. Latin America is also expected to grow at a healthy rate as a result of an increase in both private and public associations, causing an increase in the investment, thereby boosting the demand for the anti-inflammatory peptides. However, the Asia Pacific region is expected to witness lucrative growth during the forecast period owing to the rapidly improving healthcare infrastructure in the growing economies of India and China. Growing patient awareness levels among the population of this region coupled with the high unmet needs of the patients are expected to further drive this region.
The key players in the anti-inflammatory peptides market are Mylan Pharmaceuticals, Novartis AG, Rogne Bioscience, Merck Serono, F4 Pharma, Araim Pharmaceuticals, Inc., Digna Biotech, and Abbvie Corporation. The companies are involved in developing novel drugs to capture substantial market share over the forecast period.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.